hepatocellular carcinoma and intrahepatic cholangiocarcinoma and metastatic liver cancer
Conditions
Interventions
Intervention: Application of ARISTA AH followed by AdSpray on the liver resection surface
ARISTA AH is applied for hemostasis, followed by application of AdSpray. This study evaluates the safety of a
Sponsors
Okamura Yukiyasu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria will be included: 1. Patients with primary or metastatic liver tumors (hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or metastatic liver cancer) who are clinically indicated for liver resection based on liver function and tumor characteristics 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 3.Age 18 years or older, regardless of sex
Exclusion criteria
Exclusion criteria: Patients meeting any of the following criteria will be excluded: 1. Patients undergoing liver resection requiring vascular or biliary reconstruction 2. Patients with intrahepatic cholangiocarcinoma requiring lymph node dissection 3. Patients with impaired liver function (Child-Pugh class B or C) 4. Patients with tumor invasion to adjacent organs (excluding the gallbladder) 5. Patients with tumor invasion into the inferior vena cava 6. Patients deemed unsuitable for participation in this study by the principal investigator 7. Patients who decline to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of postoperative complications associated with the combined use of a hemostatic agent and an anti-adhesion material on the liver resection surface | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative laboratory abnormalities. WBC, CRP, T-Bil, AST, ALT, Cre, eGFR Imaging findings around the resection surface , scored 0-2 based on severity Adhesion score at repeat hepatectomy | — |
Contacts
Public ContactYusuke Mitsuka
Nihon University School of Medicine, Itabashi Hospital
Outcome results
None listed